Newsroom


Subcutaneous Daratumumab Plus CyBorD Improves Outcomes in AL Amyloidosis

Subcutaneous Daratumumab Plus CyBorD Improves Outcomes in AL Amyloidosis

Raymond Comenzo, MD, Tufts Medical Center, Boston, Massachusetts, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with light chain (AL) amyloidosis. These results were presented during the virtual 2020 EHA Congress.

View the video here